Comments
Aurobindo Pharma is expecting the US Food and Drug Administration (USFDA) to inspect its antibiotics production plant in Hyderabad between July and September this year as it seeks lifting a ban imposed by the American health regulator.
The drug firm’s exports to the US market have been affected due to the import alert issued by the USFDA for its Unit-VI facility since last year following manufacturing norms violation.
“We expect the FDA inspection of its Hyderabad Unit–VI to happen anywhere between July and September this year,” Aurobindo Pharma CEO (API & CRAMS), Mr N Govindarajan said.
The USFDA had audited the cephalosporin facility of the company’s Hyderabad Unit-VI in December 2010. Since then, the facility has been banned from exporting medicines produced there to the US.
Commenting on the growth prospects of the company this fiscal, he said the company is looking to grow in double digits in the current fiscal. “We are looking at in the range of 15-20 per cent,” Mr Govindarajan said.
Shares of Aurobindo Pharma today closed at Rs 110 on the BSE, up 0.90 per cent over its previous close.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.